Enteris BioPharma

Boonton, United States Founded: 2013 • Age: 13 yrs Acquired By SWK Holdings
Oral peptide delivery technology is developed for drug applications.
Request Access

About Enteris BioPharma

Enteris BioPharma is a company based in Boonton (United States) founded in 2013 was acquired by SWK Holdings in August 2019.. Enteris BioPharma offers products and services including CMC Consulting, Formulation Development, Spray Drying, and cGMP Manufacturing. Enteris BioPharma operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.

  • Headquarter Boonton, United States
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Mod3 Pharma, Inc.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    SWK Holdings

    (Aug 27, 2019)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Enteris BioPharma

Enteris BioPharma offers a comprehensive portfolio of products and services, including CMC Consulting, Formulation Development, Spray Drying, and cGMP Manufacturing. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Offers expertise in Chemistry, Manufacturing, and Controls for drugs

Develops formulations for challenging active ingredients

Engineers particles for enhanced drug bioavailability

Produces clinical supplies under good manufacturing practices

People of Enteris BioPharma
Headcount 10-50
Employee Profiles 5
Employee Profiles
People
Gary A. Shangold
Chief Medical Officer
People
Paul Shields
Chief Executive Officer
People
Thomas Daggs
VP, Product Development & Quality Control

Unlock access to complete

Funding Insights of Enteris BioPharma

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Enteris BioPharma

Enteris BioPharma has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include SWK Holdings. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Investments and advisory services are provided by the holding company.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Enteris BioPharma

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Enteris BioPharma

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Enteris Biopharma Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Enteris BioPharma

Enteris BioPharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Antibody-siRNA complexes are developed for cancer treatment.
domain founded_year HQ Location
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
domain founded_year HQ Location
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
domain founded_year HQ Location
Developing novel drugs based on a proteome-wide ligand and target discovery platform
domain founded_year HQ Location
Dental implants and regenerative dentistry products are developed.
domain founded_year HQ Location
RNA-editing technologies are provided for precision medicine applications.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Enteris Biopharma

Frequently Asked Questions about Enteris BioPharma

When was Enteris BioPharma founded?

Enteris BioPharma was founded in 2013.

Where is Enteris BioPharma located?

Enteris BioPharma is headquartered in Boonton, United States. It is registered at Boonton, New Jersey, United States.

What does Enteris BioPharma do?

Enteris BioPharma specializes in oral peptide delivery and has developed a technology called Peptelligence, which has two components enhancer and excipient. The enhancer acts as a permeation tool and loosens the tight junction of the intestinal enterocytes, whereas the excipient works as a chelating agent, easing the transport and permeating the membrane. The company has two oral drugs in the pipeline based on the above-mentioned technology Ovarest (phase 1 -endometriosis) and Tobrate (preclinical - UTI). Additionally, it provides contract manufacturing from small pre-clinical to commercial scale.

Who are the top competitors of Enteris BioPharma?

Enteris BioPharma's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.

What products or services does Enteris BioPharma offer?

Enteris BioPharma offers CMC Consulting, Formulation Development, Spray Drying, and cGMP Manufacturing.

Who are Enteris BioPharma's investors?

Enteris BioPharma has 1 investor. Key investors include SWK Holdings.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available